收藏切换
A comprehensive clinical evaluation of rIX-FP for the treatment of hemophilia B
收藏切换
Cai-hua YANG1, Yuan-yuan QI2, Zhuo-yun WANG3, Yun-cui YU4, Zheng-li DAI5, Qi-wei WANG5, Yuan-yuan WANG2, Juan CHEN1, Ping ZHENG1, Xiao-ling WANG4, *, Yi-lei LI1, *
Chinese Journal of New Drugs | 2026, 35(18) : 1988 - 1998
Less
收藏切换
Chinese Journal of New Drugs | 2026, 35(18): 1988-1998
A comprehensive clinical evaluation of rIX-FP for the treatment of hemophilia B
Full
Cai-hua YANG1, Yuan-yuan QI2, Zhuo-yun WANG3, Yun-cui YU4, Zheng-li DAI5, Qi-wei WANG5, Yuan-yuan WANG2, Juan CHEN1, Ping ZHENG1, Xiao-ling WANG4, *, Yi-lei LI1, *
Affiliations
  • 1Department of Pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
  • 2Department of Pharmacy, The Second Hospital of Anhui Medical University, Hefei 230601, China
  • 3Department of Clinical Pharmacy, Anhui Children's Hospital, Hefei 230001, China
  • 4Clinical Research Center, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China
  • 5China Pharmaceutical Industry Information Center, Shanghai 200040, China
Published: 2026-09-30 doi: 10.20251/j.cnki.1003-3734.2026.18.011
Outline
收藏切换
Objective:

To conduct a comprehensive clinical evaluation of albutrepenonacog alfa (rIX-FP) for the treatment of hemophilia B.

Methods:

Based on guidelines, literature, and publicly available data, and following the PICOS principle, rIX-FP was compared with plasma-derived FIX, standard half-life recombinant FIX (SHL rFIX), and extended half-life recombinant FIX (EHL rFIX) across five dimensions: efficacy, safety, suitability, innovation, and economy.

Results:

The evaluation results indicate that rIX-FP has potential advantages over other FIX preparations in terms of reducing the annualized bleeding rate, increasing the proportion of patients with zero bleeding events, and improving joint health, with consistent trends observed in the pediatric subgroup. The safety profile of rIX-FP is comparable to that of other recombinant FIX preparations, with no unmanageable safety risks observed. Regarding suitability, rIX-FP is available in five dosage specifications, offers flexible dosing options, and requires no special storage conditions. In terms of innovation, it utilizes albumin fusion technology to extend the half-life, thereby reducing dosing frequency and increasing trough levels. As for economy, although not yet marketed in China, international data suggest that long-term treatment (≥3 years) with rIX-FP has a cost advantage compared to SHL rFIX and rFIXFc.

Conclusion:

Based on available evidence, rIX-FP demonstrates certain clinical advantages in the treatment of hemophilia B. However, head-to-head comparative studies and local pharmacoeconomic evaluations are still warranted.

hemophilia B  /  albutrepenonacog alfa  /  extended half-life  /  coagulation factor IX  /  clinical comprehensive evaluation
杨彩华, 戚媛媛, 王卓芸, 尉耘翠, 戴铮立, 王奇巍, 王媛媛, 陈娟, 郑萍, 王晓玲, 李亦蕾. rIX-FP用于血友病B治疗的临床综合评价. 中国新药杂志, 2026 , 35 (18) : 1988 -1998 . DOI: 10.20251/j.cnki.1003-3734.2026.18.011
Cai-hua YANG, Yuan-yuan QI, Zhuo-yun WANG, Yun-cui YU, Zheng-li DAI, Qi-wei WANG, Yuan-yuan WANG, Juan CHEN, Ping ZHENG, Xiao-ling WANG, Yi-lei LI. A comprehensive clinical evaluation of rIX-FP for the treatment of hemophilia B[J]. Chinese Journal of New Drugs, 2026 , 35 (18) : 1988 -1998 . DOI: 10.20251/j.cnki.1003-3734.2026.18.011
Year 2026 volume 35 Issue 18
49
7
Cite this Article
BibTeX
Article Info
doi: 10.20251/j.cnki.1003-3734.2026.18.011
  • Online Date:2026-10-26
  • Published:2026-09-30
Article Data
Affiliations
History
  • Accepted:2026-04-28
Funding
Affiliations
    1Department of Pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
    2Department of Pharmacy, The Second Hospital of Anhui Medical University, Hefei 230601, China
    3Department of Clinical Pharmacy, Anhui Children's Hospital, Hefei 230001, China
    4Clinical Research Center, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China
    5China Pharmaceutical Industry Information Center, Shanghai 200040, China
References
Share
https://castjournals.cast.org.cn/joweb/zgxyzz/EN/10.20251/j.cnki.1003-3734.2026.18.011
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT